.
Here’s a summary of key information about AbbVie:
- Focus Areas: AbbVie concentrates on several therapeutic areas including immunology, oncology, neuroscience, and eye care, with additional efforts in areas like aesthetics, infectious diseases, pulmonology, and endocrinology.
- Products: They have a diverse portfolio of approved and investigational therapies for a wide range of conditions, including autoimmune diseases like rheumatoid arthritis and Crohn’s disease (Humira), cancers (Imbruvica), neurological disorders such as Parkinson’s and Alzheimer’s, and eye diseases like glaucoma. Their most well-known product, Humira, has generated significant revenue for the company.
- Research & Development: AbbVie invests heavily in research and development, with approximately 90 compounds, devices, or indications currently in development. They are actively pursuing new approaches to treat various diseases through innovative research and collaborations.
- Company History: AbbVie was established in 2013 as a spin-off from Abbott Laboratories, initially focusing on the research and development side of the pharmaceutical business.
- Acquisitions & Partnerships: AbbVie has expanded its capabilities through strategic acquisitions and partnerships, including Cerevel Therapeutics (neuroscience), Aliada Therapeutics (neuroscience), Nimble Therapeutics (autoimmune), and a recent licensing agreement with Ichnos Glenmark Innovation for a cancer drug candidate.
- Financial Performance: AbbVie is a significant player in the biopharmaceutical industry, ranked among the largest by revenue, according to Wikipedia. Their stock (ABBV) is traded on the NYSE, and their recent earnings and revenue have shown growth.
- Corporate Practices: AbbVie has faced accusations and settlements regarding anti-competitive practices related to patent thickets and drug pricing, as well as kickback schemes and the marketing of opioid painkillers.
In essence, AbbVie is a major biopharmaceutical company with a broad focus on developing and delivering innovative treatments for a variety of serious diseases, driven by a significant investment in research and development and a history of strategic growth through acquisitions and partnerships.
AbbVie: Key information at a glance
AbbVie is a global biopharmaceutical company focusing on the discovery, development, and commercialization of medicines and solutions for complex and serious diseases.
Here’s a summary of key information about AbbVie:
Focus areas
AbbVie concentrates on therapeutic areas such as immunology, oncology, neuroscience, and eye care, with additional efforts in areas like aesthetics, infectious diseases, pulmonology, and endocrinology.
Products
- AbbVie has a diverse portfolio of approved and investigational therapies.
- Some of their prominent products include Humira (for autoimmune diseases), Imbruvica and Venclexta (for cancers), Botox Therapeutic and Vraylar (for neurological disorders), and therapies for eye diseases like glaucoma.
- Humira, their well-known product, has historically generated significant revenue, with peak figures around $20 billion globally.
Research and Development (R&D)
- AbbVie invests heavily in R&D, with approximately 90 compounds, devices, or indications currently in development.
- They are actively pursuing new approaches through innovative research and collaborations.
- In January 2025, AbbVie partnered with Neomorph to develop new molecular glue degraders for oncology and immunology.
- In May 2025, they collaborated with ADARx Pharmaceuticals to develop a new type of RNA technology for neuroscience, immunology, and oncology.
Company history
AbbVie was established in 2013 as a spin-off from Abbott Laboratories, initially focusing on the research and development side of the pharmaceutical business.
Acquisitions and partnerships
AbbVie has expanded its capabilities through strategic acquisitions and partnerships, including:
- Neuroscience drugmaker Cerevel Therapeutics (acquired in August 2024 for $8.7 billion).
- Aliada Therapeutics (acquired in October 2024 for $1.4 billion).
- Nimble Therapeutics (acquired in January 2025 for $200 million).
- A licensing agreement with Ichnos Glenmark Innovation for a cancer drug candidate.
Financial performance
- AbbVie is a major player in the biopharmaceutical industry, ranked among the largest by revenue.
- Their stock (ABBV) is traded on the NYSE.
- In 2024, AbbVie’s total revenue was $56.33 billion.
- In the fourth quarter of 2024, worldwide net revenues were $15.102 billion, an increase of 5.6 percent.
- Humira’s net revenues decreased significantly in 2024 due to biosimilar competition.
- Skyrizi and Rinvoq, two immunology drugs, have seen substantial revenue increases, and AbbVie has raised its long-term outlook for their combined revenues.
Corporate practices
- AbbVie has faced accusations and settlements regarding anti-competitive practices, including using a “patent thicket” around Humira to extend its market exclusivity.
- The company was sued in the Netherlands for allegedly abusing its dominant position and violating human rights by charging excessive prices for Humira.
- AbbVie has also faced lawsuits alleging kickback schemes and the use of “nurse ambassadors” to promote Humira.
- In 2018, the FDA issued a report stating that AbbVie failed to properly investigate patient deaths, a significant quality-control failure.
- In 2022, AbbVie agreed to pay up to $2.37 billion to settle lawsuits related to the marketing of opioid painkillers by its Allergan unit.
Leadership changes
- Richard Gonzalez, who served as AbbVie’s CEO since its launch in 2013, stepped down in July 2024 and became the Executive Chairman.
- He was replaced by Robert A. Michael, the former President and Chief Operating Officer, who also joined the company’s Board of Directors.
- Michael has over 30 years of experience in leadership roles across multiple businesses, including pharmaceuticals, aesthetics, diagnostics, diabetes care, and nutrition.
AbbVie, एक प्रमुख वैश्विक बायोफार्मास्युटिकल कंपनी है जो जटिल और गंभीर बीमारियों के लिए दवाओं और समाधानों की खोज, विकास, निर्माण और व्यावसायीकरण के लिए समर्पित है। यहाँ कुछ महत्वपूर्ण समाचार और जानकारी दी गई है:
हालिया गतिविधियां और साझेदारियां
- ग्लेनमार्क के साथ बड़ी डील: हाल ही में, एबवी ने ग्लेनमार्क फार्मा की सहायक कंपनी इच्नोस ग्लेनमार्क इनोवेशन (आईजीआई) के साथ ISB-2001 नामक कैंसर दवा उम्मीदवार के लिए एक विशेष लाइसेंसिंग समझौता किया है.
- इस समझौते के तहत, ग्लेनमार्क को शुरू में 70 मिलियन डॉलर की अग्रिम राशि मिलेगी.
- क्लिनिकल ट्रायल, रेगुलेटरी अप्रूवल और वैश्विक बिक्री लक्ष्यों को पूरा करने पर ग्लेनमार्क को कुल 700 मिलियन डॉलर तक की राशि मिल सकती है.
- इस खबर के बाद, 11 जुलाई 2025 को ग्लेनमार्क फार्मा के शेयरों में 10% की तेजी देखने को मिली.
- सीईओ में बदलाव: जुलाई 2024 में, रिचर्ड गोंजालेज ने सीईओ के पद से इस्तीफा दे दिया और रॉबर्ट ए. माइकल ने उनकी जगह ली.
प्रमुख उत्पाद और अनुसंधान
- AbbVie का प्रमुख उत्पाद हुमीरा (Humira) है, जिसका उपयोग ऑटोइम्यून बीमारियों के इलाज के लिए किया जाता है।
- कंपनी कैंसर, तंत्रिका संबंधी बीमारियों, नेत्र देखभाल और सिस्टिक फाइब्रोसिस के उपचारों पर भी ध्यान केंद्रित कर रही है।
- AbbVie की पाइपलाइन में पार्किंसंस रोग के लिए दवाएं भी शामिल हैं।
- AbbVie की पाइपलाइन में विभिन्न चरणों में कई कार्यक्रम हैं।
भारत में उपस्थिति
- AbbVie थेरप्यूटिक्स इंडिया प्राइवेट लिमिटेड, जो पहले एलर्जन इंडिया प्राइवेट लिमिटेड के नाम से जानी जाती थी, भारत में एबवी का परिचालन करती है। यह एलर्जन और पिरामल फार्मा लिमिटेड का एक संयुक्त उद्यम है जिसने 1996 में परिचालन शुरू किया।
वित्तीय प्रदर्शन
- AbbVie राजस्व के मामले में अग्रणी बायोमेडिकल कंपनियों में से एक है।
- हुमीरा की बढ़ती लागत विवादास्पद रही है और यह उन दवाओं में से एक थी जिसे मुद्रास्फीति न्यूनीकरण अधिनियम द्वारा लक्षित किया गया था।
अन्य जानकारी
- AbbVie की स्थापना 2013 में एबॉट से अलग होकर हुई थी। इसका नाम एबॉट के नाम से “एबी” और “जीवन” के लिए लैटिन मूल के “वी” को मिलाकर रखा गया है।